Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Dec 15;22(24):6301.
doi: 10.1158/1078-0432.CCR-16-2351.

Individualized Tamoxifen Dose Escalation-Response

Affiliations
Comment

Individualized Tamoxifen Dose Escalation-Response

Daniel L Hertz et al. Clin Cancer Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: No potential conflicts of interest

Comment on

References

    1. Hertz DL, Rae JM. Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility. Clin Cancer Res 2016;22(13):3121–3 doi 10.1158/1078-0432.ccr-16-0370. - DOI - PMC - PubMed
    1. Lintermans A, Van Asten K, Jongen L, Blomme C, Lambrechts D, Van Calster B, et al. Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting. ASCO Meeting Abstracts 2016;34(15_suppl):523.
    1. Stearns V, O’Neill AM, Schneider BP, Flockhart DA, Skaar TC, Liu MC, et al. A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. ASCO Meeting Abstracts 2016;34(15_suppl):546.
    1. Isaacs D, Fitzgerald D. Seven alternatives to evidence-based medicine. Oncologist 2001;6(4):390–1. - PubMed
    1. Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, et al. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. The oncologist 2016;21(7):795–803 doi 10.1634/theoncologist.2015-0480. - DOI - PMC - PubMed

LinkOut - more resources